



**KDIGO SESSION: PRECISION MEDICINE IN
IgAN TREATMENT: SELECTING THE RIGHT
THERAPIES FOR THE RIGHT PATIENT AT THE
RIGHT TIME**

2025 ANZSN Congress



SUPPORT

This session is supported by an unrestricted educational grant from Novartis

SPEAKERS



Meg Jardine, MBBS, PhD
University of Sydney



Muh Geot Wong, MBBS, PhD, FRACP
University of Sydney



KDIGO INTRO & OVERVIEW

Meg Jardine

THE KDIGO MISSION



Improving the care and outcomes of kidney disease patients worldwide through the development and implementation of global clinical practice guidelines.

INTRO TO KDIGO



- KDIGO is a global nonprofit organization, incorporated in Belgium, developing and implementing evidence-based clinical practice guideline in kidney disease
- 3 core businesses of KDIGO
 - Clinical Practice Guidelines
 - Controversies Conferences & Summits
 - Implementation & Education



CLINICAL PRACTICE GUIDELINES

2025 KDIGO GUIDELINE PUBLICATIONS

- **ADPKD:** February 2025
- **Nephrotic Syndrome in Children:** April 2025
- **IgAN and IgAV:** Online publication September 2025
- **Anemia in CKD:** Online publication January 2026





CONTROVERSIES CONFERENCES & SUMMITS

WHAT IS A CONTROVERSIES CONFERENCE?

- Invitation-only meetings that bring together recognized experts, patients, and healthcare professionals in nephrology
- Aim is to debate, discuss, and determine what we know and what we don't know regarding important unresolved issues in kidney disease
 - What do we know?
 - What can we do with what we know?
 - What don't we know yet?
- Provides a platform for exchange of the latest scientific evidence in a specific topic area
- Controversies Conferences result in a published Conference Report
 - Puts forth a suggested research agenda
 - The resulting publication is not a guideline

RECENT CONTROVERSIES CONFERENCE REPORTS

CKD-MBD

Prevention of CKD

APOL1 Kidney Disease

In progress:
Heart Failure in CKD

Obesity in CKD

Green Dialysis

B-Cell

Chronic kidney disease–mineral and bone disorder: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference



OPEN

Markus Ketteler¹, Pieter Evenepoel^{2,3}, Rachel M. Holden⁴, Tamara Isakova⁵, Hanne Skou Jørgensen^{6,7}, Hirotaka Komaba⁸, Thomas L. Nickolas⁹, Smeeta Sinha^{10,11}, Marc G. Vervloet¹², Michael Cheung¹³, Jennifer M. King¹³, Morgan E. Grams¹⁴, Michel Jadoul¹⁵ and Rosa M.A. Moysés¹⁶; for Conference Participants¹⁷

¹Department of General Internal Medicine and Nephrology, Robert-Bosch-Hospital, Stuttgart, Germany; ²Department of Microbiology, Immunology and Transplantation, Nephrology and Renal Transplantation Research Group, Katholieke Universiteit Leuven, Leuven, Belgium; ³Department of Nephrology and Renal Transplantation, University Hospitals Leuven, Leuven, Belgium; ⁴Department of Medicine, Queen's University, Kingston, Ontario, Canada; ⁵Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA; ⁶Department of Nephrology, Aalborg University Hospital, Aalborg, Denmark; ⁷Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; ⁸Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan; ⁹Department of Medicine, Division of Bone and Mineral Diseases, Washington University School of Medicine, St Louis, Missouri, USA; ¹⁰Renal Directorate, Northern Care Alliance NHS Foundation Trust, Salford, UK; ¹¹Manchester Academic Health Sciences Centre, University of Manchester, Manchester, UK; ¹²Department of Nephrology, Radboud University Medical Center, Nijmegen, the Netherlands; ¹³KDIGO, Brussels, Belgium; ¹⁴Department of Medicine, New York University Langone School of Medicine, New York, New York, USA; ¹⁵Cliniques Universitaires Saint Luc, Université Catholique de Louvain, Brussels, Belgium; and ¹⁶Laboratório de Fisiopatologia Renal (LIM 16), Nephrology Department, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), Universidade de São Paulo, São Paulo, Brazil

In 2017, Kidney Disease: Improving Global Outcomes (KDIGO) published a Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD). Since then, new lines of evidence have been published related to evaluating disordered mineral metabolism and bone quality and turnover, identifying and inhibiting vascular calcification, targeting vitamin D levels, and regulating parathyroid hormone. For an in-depth consideration of the new insights, in October 2023, KDIGO held a Controversies Conference on CKD-MBD: Progress and Knowledge Gaps Toward Personalizing Care. Participants concluded that the recommendations in the 2017 CKD-MBD guideline remained largely consistent with the available evidence. However, the framework of the 2017 Guideline, with 3 major sections—biochemical abnormalities in mineral metabolism; bone disease; and vascular calcification—may no longer best reflect currently available evidence related to diagnosis and treatment. Instead, future guideline efforts could consider mineral

homeostasis and deranged endocrine systems in adults within a context of 2 clinical syndromes: CKD-associated osteoporosis, encompassing increased fracture risk in patients with CKD; and CKD-associated cardiovascular disease, including vascular calcification and structural abnormalities, such as valvular calcification and left ventricular hypertrophy. Participants emphasized that the complexity of bone and cardiovascular manifestations of CKD-MBD necessitates personalized approaches to management.

Kidney International (2025) 107, 405–423; <https://doi.org/10.1016/j.kint.2024.11.013>

KEYWORDS: calcium; CKD-MBD; parathyroid hormone; phosphate; renal osteodystrophy; vitamin D

Copyright © 2024, Kidney Disease: Improving Global Outcomes (KDIGO). Published by Elsevier Inc. on behalf of the International Society of Nephrology. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Correspondence: Rosa M.A. Moysés, Rua Iperóia, 690 ap 121, São Paulo SP 05016-000, Brazil. E-mail: rosa.moyses@uacl.com.br; or Markus Ketteler, General Internal Medicine and Nephrology, Robert-Bosch-Hospital, Auerbachstrasse 110, 70376 Stuttgart, Germany. E-mail: markus.ketteler@rbk.de

¹⁷Additional Conference Participants are listed in the Appendix.

Received 7 October 2024; revised 14 November 2024; accepted 18 November 2024



IMPLEMENTATION & EDUCATION

WHAT IS AN IMPLEMENTATION SUMMIT?

- Summits take a deep dive into existing guidelines or published conference reports
- Applicability in specific countries or regions
- Explore barriers to implementation
- Focus on strategies to overcome barriers and improve current practice

COLLABORATIONS

- MOUs with ISN, ERA, APSN, SLANH, WONCA, AFRAN

Working with:




- ASN
- NKF
- PCDE
- ISGD



KDIGO Podcasts

Upcoming Conversations in Nephrology Podcast Series

- *APOL1* Kidney Disease
- Complement in Kidney Disease
- IgAN & FSGS



RECENT WEBINARS

- **Medscape Anemia 4-Part Webinar Series**
October 2024 – February 2025 (Medscape)
- **ISN-KDIGO Webinar: Nurses Workshop**
November 2024

- **Unraveling IgA Nephropathy: Understanding Key Drivers of Disease Progression**

November 2024 (Medlive)

- **Implementing Genetic Testing for CKD in a Real-World Setting 4-part Webinar Series**
November 2024 – February 2025

- **Advancing IgA Nephropathy Management: New KDIGO Recommended Therapeutic Strategies**

January 2025 (Medlive)

- **Hot Topics in IgAN**

January 2025 (SkyMed)

- **Mastering Chronic Kidney Disease Care in Type 2 Diabetes: Clinical Case Conversations**

February 2025 (Medscape)



KDIGO 2025 IgAN Guideline Update: A New Framework for Management and Therapeutic Approach

Muh Geot Wong